Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 11/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | MT-ND4 | P03905 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rotenone SCHEMBL20152380 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E | |
| Rotenone SCHEMBL29388856 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E | |
| Rotenone SCHEMBL13845713 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E | |
| Rotenone SCHEMBL13926662 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E | |
| Rotenone SCHEMBL42253 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E | |
| Rotenone SCHEMBL29351552 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E | |
| Rotenone SCHEMBL19019920 | 1.00 | CYP3A4 (1.00) | CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E | |
| Rotenone SCHEMBL5490007 | 0.99 | CYP3A4 (0.98) | CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E | |
| Rotenone SCHEMBL7142434 | 0.97 | CYP3A4 (0.95) | CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E | |
| Rotenone SCHEMBL8386940 | 0.96 | CYP3A4 (0.93) | CYP3A4MAPTSMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0141373-B1 | DELIVERY SYSTEM FOR MERISTEMATIC TISSUE | PLANT GENETICS, INC. (US) | 1991-10-16 | — | — | EP | claimed |
| EP-3363426-B1 | COMPOSITION FOR SKIN WHITENING CONTAINING AMORPHIGENI AS ACTIVE INGREDIENT | NAT UNIV GYEONGSANG IACF (KR) | 2021-06-16 | — | — | EP | disclosed |
| US-20120276006-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-8226929-B2 | Administering to a patient a contrast agent (pyridimifen, fenazaquin) which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20090136424-A1 | Rotanone Analogs: Method of Preparation and Use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-05-28 | — | — | US | disclosed |
| US-20080112884-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-7344702-B2 | Contrast agents for myocardial perfusion imaging | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080112884-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | CYP3A4 3831/4885MAPT 4043/4885SMN1; SMN2 2969/4885 |
| US-20090136424-A1 | Rotanone Analogs: Method of Preparation and Use | NDUFB5, NDUFB10, NDUFB3 | CYP3A4 510/4885MAPT 3737/4885SMN1; SMN2 1695/4885 |
| US-20120276006-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | CYP3A4 3831/4885MAPT 4043/4885SMN1; SMN2 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.